Expression_of_shared_idiotypes_in_chronic_lymphocytic_leukemia_and_small_lymphocytic_lymphoma._The_expression_of_shared_idiotypes_(Slds)_has_been_studied_on_malignant_CD5+B_cells_from_patients_with_chronic_lymphocytic_leukemia_(CLL)_and_small_lymphocytic_lymphoma_(SLL)_using_a_panel_of_37_murine_monoclonal_antibodies_previously_demonstrated_to_be_reactive_with_Slds_derived_from_follicular_B-cell_lymphomas._Thirteen_anti-Slds_identified_tumor_cells_from_31_of_105_(30%)_CLL_patients_and_4_of_6_SLL_patients._In_comparison,_the_same_panel_of_anti-Slds_is_reactive_with_33%_of_follicular_and_diffuse_B-cell_lymphomas._Ten_of_these_anti-Slds_reacted_with_CLL_cases_at_similar_frequencies_to_that_of_the_B-cell_lymphomas._Two_anti-Slds,_which_are_known_to_react_with_autoantibodies,_were_significantly_more_prevalent_in_CLL_than_in_B-cell_lymphomas._These_data_confirm_the_presence_of_Slds_in_CLL_and_provide_further_evidence_of_an_association_between_CLL_and_autoimmunity._The_identification_of_a_panel_of_antibodies_reactive_with_a_significant_number_of_CLL_and_SLL_patients_will_facilitate_the_application_of_anti-idiotype_antibody_therapy_in_these_diseases.